Dolutegravir/lamivudine
Combination drug / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Dovato?
Summarize this article for a 10 year old
Dolutegravir/lamivudine, sold under the brand name Dovato, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. each pill contains 50 mg dolutegravir, as the salt, an integrase strand transfer inhibitor (INSTI), and 300 mg lamivudine, a nucleoside analogue reverse transcriptase inhibitor (NRTI).[4][5] It is taken by mouth.[4][5]
Combination of | |
---|---|
Dolutegravir | Integrase inhibitor |
Lamivudine | Reverse-transcriptase inhibitor |
Clinical data | |
Trade names | Dovato |
AHFS/Drugs.com | Monograph |
MedlinePlus | a619043 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
KEGG |
It was approved for use in the United States in April 2019,[4][6][7] and in the European Union in July 2019,[5] and again with revisions in June 2022.[5][8]
The most common side effects are headache, diarrhea, nausea, and difficulty sleeping.[5] The most common serious side effects are allergic reactions, including rash and severe liver problems.[5]
Dolutegravir/lamivudine is the first FDA-approved two-drug, fixed-dose, complete regimen for HIV-infected adults who have never received treatment for HIV.[7]